1. Home
  2. DXCM vs BEKE Comparison

DXCM vs BEKE Comparison

Compare DXCM & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DXCM
  • BEKE
  • Stock Information
  • Founded
  • DXCM 1999
  • BEKE 2001
  • Country
  • DXCM United States
  • BEKE China
  • Employees
  • DXCM N/A
  • BEKE N/A
  • Industry
  • DXCM Medical/Dental Instruments
  • BEKE Real Estate
  • Sector
  • DXCM Health Care
  • BEKE Finance
  • Exchange
  • DXCM Nasdaq
  • BEKE Nasdaq
  • Market Cap
  • DXCM 28.0B
  • BEKE 24.7B
  • IPO Year
  • DXCM 2005
  • BEKE 2020
  • Fundamental
  • Price
  • DXCM $80.89
  • BEKE $19.49
  • Analyst Decision
  • DXCM Buy
  • BEKE Strong Buy
  • Analyst Count
  • DXCM 17
  • BEKE 4
  • Target Price
  • DXCM $101.29
  • BEKE $25.97
  • AVG Volume (30 Days)
  • DXCM 4.0M
  • BEKE 8.3M
  • Earning Date
  • DXCM 10-24-2024
  • BEKE 11-21-2024
  • Dividend Yield
  • DXCM N/A
  • BEKE 1.84%
  • EPS Growth
  • DXCM 83.21
  • BEKE N/A
  • EPS
  • DXCM 1.67
  • BEKE 0.50
  • Revenue
  • DXCM $3,954,000,000.00
  • BEKE $11,766,571,657.00
  • Revenue This Year
  • DXCM $13.10
  • BEKE $13.86
  • Revenue Next Year
  • DXCM $14.79
  • BEKE $11.10
  • P/E Ratio
  • DXCM $47.58
  • BEKE $37.44
  • Revenue Growth
  • DXCM 16.19
  • BEKE 11.06
  • 52 Week Low
  • DXCM $62.34
  • BEKE $12.44
  • 52 Week High
  • DXCM $142.00
  • BEKE $26.05
  • Technical
  • Relative Strength Index (RSI)
  • DXCM 62.87
  • BEKE 45.31
  • Support Level
  • DXCM $77.50
  • BEKE $18.51
  • Resistance Level
  • DXCM $80.18
  • BEKE $19.62
  • Average True Range (ATR)
  • DXCM 2.52
  • BEKE 0.71
  • MACD
  • DXCM 0.41
  • BEKE -0.13
  • Stochastic Oscillator
  • DXCM 78.47
  • BEKE 45.94

About DXCM DexCom Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

About BEKE KE Holdings Inc (each representing three)

KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2023, Beike's cofounders collectively control the company, while Tencent and its affiliates share 8% of voting power.

Share on Social Networks: